

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[← Back](#)

[Biostatistics](#)

[Refer a Patient](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)



Email

iasonosa@mskcc.org

Education

University of Albany

Current Research Interests

Dr. Iasonos has been at MSKCC since 2005. She has collaborated primarily with investigators studying ovarian cancer and also with investigative teams studying bladder cancer, lymphoma, and health outcomes. Through her collaborations with investigators in gynecology (Departments of Surgery, Medicine and Pathology) she is exploring various biomarkers and assessing relationships to histology, metastasis and clinical outcome. She is also involved in vaccine trials as a second line therapy in ovarian cancer patients, and in identifying valid endpoints for these trials. Her methodological interests focus on model-based designs that guide the dose escalation in phase I trials and in the past few years she has focused on the design of early phase trials that involve dose expansion cohorts.

Publications

Selected peer-reviewed publications:

Iasonos A, O'Quigley J. Dose expansion cohorts in Phase I trials. *Stat Biopharm Res.* 2016;8(2):161-170. Epub 2016 Jun 2. PubMed PMID: 27516848; PubMed Central PMCID: PMC4976787.

Iasonos A, O'Quigley J. Clinical trials: Early phase clinical trials-are dose expansion cohorts needed? *Nat Rev Clin Oncol.* 2015 Nov;12(11):626-8. doi:10.1038/nrclinonc.2015.174. Epub 2015 Oct 6. PubMed PMID: 26441082; PubMed Central PMCID: PMC4758199.

Satagopan JM, Iasonos A. Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale. *Contemp Clin Trials.* 2017 Feb 22. pii: S1551-7144(16)30093-3. doi: 10.1016/j.cct.2017.02.007. [Epub ahead of print] PubMed PMID: 28254404.

Iasonos A, O'Quigley J. Adaptive dose-finding studies: a review of model-guided phase I clinical trials. *J Clin Oncol.* 2014 Aug 10;32(23):2505-11. doi: 10.1200/JCO.2013.54.6051. Epub 2014 Jun 30. Review. PubMed PMID: 24982451; PubMed Central PMCID: PMC4121508.

Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol.* 2008 Mar 10;26(8):1364-70. doi: 10.1200/JCO.2007.12.9791. Review.

[Visit PubMed for a full listing of Alexia Iasonos' journal articles](#)

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

My Downloads

[R code Journal of the Royal Statistical Society entitled 'Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events'.](#)

[Time to publication of oncology trials and why some trials are never published](#)

My Pages

[Is the Continual Reassessment Method Superior to the Standard 3+3 Dose Escalation Scheme?
Phase I Workshop](#)

My Projects

[Statistical Methods for Evaluating Predictive Cancer Biomarkers](#)

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Alexia Iasonos discloses the following relationships and financial interests:

Baruch College

Professional Services and Activities

Chapman and Hall

Intellectual Property Rights

Intelligencia Inc.

Professional Services and Activities

Journal of Clinical Oncology

Professional Services and Activities

Mirati Therapeutics

Professional Services and Activities (Uncompensated)

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies [here](#). For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

[View all disclosures](#) →

PREVIOUS

[Glenn Heller](#)

NEXT

[Hannah Kalvin](#)

▾ [Connect](#)

[Contact us](#)

[Locations](#)

APPOINTMENTS

[800-525-2225](#)



▾ About MSK

[About us](#)

[Careers](#) 

[Giving](#) 

▾ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

▾ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) 

[Graduate medical education](#)

[MSK Library](#) 

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center